Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	phosphatidylinositol-4-phosphate binding	OBSCN LANCL2 SAP30L PLA2G4E OSBP	4.72e-05	36	223	5	GO:0070273
GeneOntologyMolecularFunction	phosphatidylinositol-5-phosphate binding	OBSCN LANCL2 SAP30L PLA2G4E	1.13e-04	23	223	4	GO:0010314
GeneOntologyMolecularFunction	glycosylceramidase activity	LCT GBA3	1.24e-04	2	223	2	GO:0017042
HumanPheno	Short palm	ATP7A WDR81 EVC TONSL WDR35 FGFR3 COG4 FLNA B3GLCT IGF1R	1.27e-05	118	80	10	HP:0004279
HumanPheno	Abnormality of the capitate bone	ATP7A EVC FGFR3 FLNA	2.54e-05	12	80	4	HP:0004262
HumanPheno	Abnormality of the hamate bone	ATP7A EVC FGFR3 FLNA	2.54e-05	12	80	4	HP:0004259
HumanPheno	Capitate-hamate fusion	ATP7A EVC FGFR3 FLNA	2.54e-05	12	80	4	HP:0001241
MousePheno	increased Deiters cell number	SPRY2 FGFR3 NR2F1	2.06e-06	3	179	3	MP:0004840
Domain	ATPase_dyneun-rel_AAA	MDN1 DNAH8 DNAH2 DNAH1	1.83e-05	14	224	4	IPR011704
Domain	AAA_5	MDN1 DNAH8 DNAH2 DNAH1	1.83e-05	14	224	4	PF07728
Domain	ARM-type_fold	USP34 VPS11 USP9X SCYL1 TELO2 ANKAR UBR4 USP24 ARFGEF2 VIRMA MROH1 HEATR9 STAG3 HTT	6.35e-05	339	224	14	IPR016024
Domain	ACTININ_2	DMD FLNA SYNE1 MACF1	1.49e-04	23	224	4	PS00020
Domain	ACTININ_1	DMD FLNA SYNE1 MACF1	1.49e-04	23	224	4	PS00019
Domain	Actinin_actin-bd_CS	DMD FLNA SYNE1 MACF1	1.49e-04	23	224	4	IPR001589
Domain	WD40_repeat_dom	VPS11 WDR81 FBXW2 ARHGEF17 NWD2 EML5 WDR35 BOP1 WDR7 UBR4 WDR12 CFAP44	2.59e-04	297	224	12	IPR017986
Domain	Ryanodine_rcpt	RYR1 RYR2	4.26e-04	3	224	2	IPR003032
Domain	CPT_N	CPT1A CPT1B	4.26e-04	3	224	2	IPR032476
Domain	Ryanrecept_TM4-6	RYR1 RYR2	4.26e-04	3	224	2	IPR009460
Domain	RyR	RYR1 RYR2	4.26e-04	3	224	2	PF02026
Domain	RR_TM4-6	RYR1 RYR2	4.26e-04	3	224	2	PF06459
Domain	CPT_N	CPT1A CPT1B	4.26e-04	3	224	2	PF16484
Domain	Ryan_recept	RYR1 RYR2	4.26e-04	3	224	2	IPR013333
Domain	Dynein_heavy_chain_D4_dom	DNAH8 DNAH2 DNAH1	5.62e-04	14	224	3	IPR024317
Domain	Dynein_HC_stalk	DNAH8 DNAH2 DNAH1	5.62e-04	14	224	3	IPR024743
Domain	Dynein_heavy_dom-2	DNAH8 DNAH2 DNAH1	5.62e-04	14	224	3	IPR013602
Domain	DHC_N2	DNAH8 DNAH2 DNAH1	5.62e-04	14	224	3	PF08393
Domain	MT	DNAH8 DNAH2 DNAH1	5.62e-04	14	224	3	PF12777
Domain	AAA_8	DNAH8 DNAH2 DNAH1	5.62e-04	14	224	3	PF12780
Domain	DHC_fam	DNAH8 DNAH2 DNAH1	6.96e-04	15	224	3	IPR026983
Domain	Dynein_heavy	DNAH8 DNAH2 DNAH1	6.96e-04	15	224	3	PF03028
Domain	Dynein_heavy_dom	DNAH8 DNAH2 DNAH1	6.96e-04	15	224	3	IPR004273
Domain	-	VPS11 WDR81 FBXW2 ARHGEF17 NWD2 EML5 WDR35 BOP1 WDR7 SEMA3D WDR12 CFAP44	7.20e-04	333	224	12	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	VPS11 WDR81 FBXW2 ARHGEF17 NWD2 EML5 WDR35 BOP1 WDR7 SEMA3D WDR12 CFAP44	7.58e-04	335	224	12	IPR015943
Domain	Glyco_hydro_1_N_CS	LCT GBA3	8.46e-04	4	224	2	IPR033132
Domain	Glyco_hydro_1_AS	LCT GBA3	8.46e-04	4	224	2	IPR018120
Domain	Post-SET_dom	EHMT2 NSD1 KMT2D	8.49e-04	16	224	3	IPR003616
Domain	PostSET	EHMT2 NSD1 KMT2D	8.49e-04	16	224	3	SM00508
Domain	POST_SET	EHMT2 NSD1 KMT2D	8.49e-04	16	224	3	PS50868
Domain	IQ	MYO7A MYO7B OBSCN IQGAP3 ADGB MYH15	8.90e-04	93	224	6	PS50096
Domain	CH	DMD IQGAP3 FLNA SYNE1 MACF1	1.09e-03	65	224	5	SM00033
Domain	Ank_2	EHMT2 ANKAR HACE1 TONSL ANKRD50 ANKRD36B ANKRD44 ANKEF1 ANKRD17	1.19e-03	215	224	9	PF12796
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	USP34 SPRY2 RIN3 MYO7A OBSCN RYR1 TAOK2 CDR2L MDN1 PKD1 SNX8 ZC3H7B SIPA1L2 CHPF SCARA3 PREX1 IQGAP3 DOC2A FLNA POLG UBR4 NSD1 AKNA ARFGEF2 RHOT2 NR2F2 KMT2D IGF1R AATK MROH1 DNAJC14 NISCH IL17RD ARHGAP33 HTT	9.86e-15	1105	226	35	35748872
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	NRIP1 MYO7A USP9X ZNF568 RYR1 RYR2 C17orf75 MDN1 PREX1 TBX4 UBR4 USP24 DNAH2 ZDBF2 RHOT2 VIRMA ANKRD36B OSBP KMT2D GTF2H3 ANKRD17 TIGD5 IL17RD	4.09e-11	638	226	23	31182584
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	USP34 OBSCN LANCL2 ZNF568 NEMP2 C5orf34 EML5 BOP1 TAOK1 COG4 FLNA TICRR POLG FRMPD1 NSD1 NUDT16L1 RHOT2 ANKRD50 TIMP3 VCAN ANKRD17 MACF1 CDC27 IL17RD	1.99e-07	1084	226	24	11544199
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	USP34 NRIP1 SPRY2 USP9X ZEB2 UBA7 MAN1A2 EHMT2 PKD1 PRMT2 TAOK1 DCLK2 CHPF PREX1 COG4 VCPIP1 SYNE1 POLG UBR4 MYRIP ARFGEF2 INTS8 DNAJC14 GUCY1B1 NISCH MACF1	3.37e-07	1285	226	26	35914814
Pubmed	USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.	MYO7B ARHGEF17 CDR2L MDN1 DMD FLNA SYNE1 NSD1 VIRMA KMT2D MACF1	4.38e-07	234	226	11	36243803
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	USP34 NRIP1 RREB1 ZEB2 EHMT2 VCPIP1 FLNA UBR4 USP24 ZDBF2 BRMS1L KMT2D ZFHX4 ANKRD17	7.26e-07	418	226	14	34709266
Pubmed	LMBR1L regulates lymphopoiesis through Wnt/β-catenin signaling.	PDXDC1 USP9X SCYL1 TAOK2 TRAFD1 TELO2 CHPF IQGAP3 VCPIP1 FLNA UBR4 USP24 DNAH2 RHOT2 CPT1A CLSTN1 INTS8 NR2F1 NISCH ANKRD17 SLC47A1	1.08e-06	942	226	21	31073040
Pubmed	iNOS is not responsible for RyR1 S-nitrosylation in mdx mice with truncated dystrophin.	RYR1 DMD NOS1	1.08e-06	4	226	3	32693782
Pubmed	Efficient generation and mapping of recessive developmental mutations using ENU mutagenesis.	RYR1 PKD1 IGF1R	2.68e-06	5	226	3	11818962
Pubmed	The Crystal Structure of the Ubiquitin-like Domain of Ribosome Assembly Factor Ytm1 and Characterization of Its Interaction with the AAA-ATPase Midasin.	MDN1 BOP1 WDR12	2.68e-06	5	226	3	26601951
Pubmed	The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells.	USP34 USP9X ZEB2 MDN1 EHMT2 IQGAP3 UBR4 USP24 ZDBF2 ZFHX4 MACF1	2.71e-06	282	226	11	23667531
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	DOCK4 ARHGEF17 ZEB2 SIPA1L2 VCPIP1 WDR7 SYNE1 FRMPD1 VIRMA EPG5 MROH1 NISCH MACF1	3.06e-06	407	226	13	12693553
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	USP34 RREB1 TRAFD1 EML5 TELO2 EHMT2 SIPA1L2 SAP30L BRD3 RHOT2 BRMS1L SIRT1 TTC7A ZFHX4 ANKRD17 MACF1 LRRC8B TIGD5 CDC27 ARHGAP33 CDH16 PHLDB2	4.33e-06	1116	226	22	31753913
Pubmed	Fibroblast growth factor receptor 3 kinase domain mutation increases cortical progenitor proliferation via mitogen-activated protein kinase activation.	SPRY2 FGFR3 NR2F1	5.34e-06	6	226	3	17181553
Pubmed	Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro.	HACE1 WDR35 TAOK1 SIPA1L2 PREX1 UBR4 VIRMA DNAH1	7.74e-06	153	226	8	10718198
Pubmed	Functional proteomics mapping of a human signaling pathway.	ZEB2 RYR2 MAN1A2 PKD1 CHPF VCPIP1 FLNA TBX4 UBR4 ARFGEF2 RHOT2 NR2F2 EPG5 KMT2D MACF1	8.68e-06	591	226	15	15231748
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	MYLK VEZF1 FAM178B NMRAL1 ZEB2 RYR2 MDN1 PMPCA UMODL1 PKHD1 DMD SIPA1L2 DNAH8 PREX1 DOC2A FLNA SYNE1 UBR4 DNAH2 MYRIP BRD3 ETHE1 MACF1 MYH15 CDC27	8.78e-06	1442	226	25	35575683
Pubmed	Isolation of several human axonemal dynein heavy chain genes: genomic structure of the catalytic site, phylogenetic analysis and chromosomal assignment.	DNAH8 DNAH2 DNAH1	9.30e-06	7	226	3	9256245
Pubmed	A signature motif mediating selective interactions of BCL11A with the NR2E/F subfamily of orphan nuclear receptors.	NSD1 NR2F1 NR2F2 RORA	1.16e-05	22	226	4	23975195
Pubmed	The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity.	PKD1 PKHD1 SLC12A1	1.48e-05	8	226	3	20215348
Pubmed	Isolation, characterization, and chromosomal localization of mouse and human COUP-TF I and II genes.	NR2F1 NR2F2 IGF1R	2.21e-05	9	226	3	8530078
Pubmed	E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins.	SPRY2 MYO7A OBSCN ARHGEF17 RYR1 MDN1 PKD1 PKHD1 SNX31 TICRR UBR4 DNAH2 BRD3 CPT1B PCIF1 CFAP44	2.90e-05	736	226	16	29676528
Pubmed	AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis.	RYR1 RYR2 DMD	3.14e-05	10	226	3	18434328
Pubmed	Human Immunodeficiency Virus Type 1 Vpr Mediates Degradation of APC1, a Scaffolding Component of the Anaphase-Promoting Complex/Cyclosome.	SCYL1 ZC3H7B SIPA1L2 VCPIP1 NUDT19 NSD1 VIRMA ANKRD17 CDC27	3.21e-05	242	226	9	34011540
Pubmed	Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase I (CPT1) gene interact with fat intake to modulate indices of obesity in French-Canadians.	CPT1A CPT1B	4.20e-05	2	226	2	17089095
Pubmed	Crosstalk between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in mice with Duchenne muscular dystrophy.	RYR2 DMD	4.20e-05	2	226	2	26555638
Pubmed	mdx muscle pathology is independent of nNOS perturbation.	DMD NOS1	4.20e-05	2	226	2	9536086
Pubmed	The bivariate NRIP1/ZEB2 RNA marker permits non-invasive presymptomatic screening of pre-eclampsia.	NRIP1 ZEB2	4.20e-05	2	226	2	33318568
Pubmed	Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans.	LCT GBA3	4.20e-05	2	226	2	12594539
Pubmed	The susceptibility of muscle cells to oxidative stress is independent of nitric oxide synthase expression.	DMD NOS1	4.20e-05	2	226	2	11268022
Pubmed	Ryanodine receptor oligomeric interaction: identification of a putative binding region.	RYR1 RYR2	4.20e-05	2	226	2	14722100
Pubmed	Molecular clues about the dystrophin-neuronal nitric oxide synthase interaction: a theoretical approach.	DMD NOS1	4.20e-05	2	226	2	24063785
Pubmed	Genetic reduction of the extracellular matrix protein versican attenuates inflammatory cell infiltration and improves contractile function in dystrophic mdx diaphragm muscles.	DMD VCAN	4.20e-05	2	226	2	32632164
Pubmed	Structural and functional interactions within ryanodine receptor.	RYR1 RYR2	4.20e-05	2	226	2	26009179
Pubmed	Localization of transcripts of the related nuclear orphan receptors COUP-TF I and ARP-1 in the adult mouse brain.	NR2F1 NR2F2	4.20e-05	2	226	2	7609634
Pubmed	Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase.	DMD NOS1	4.20e-05	2	226	2	9681470
Pubmed	Overlapping expression of ARFGEF2 and Filamin A in the neuroependymal lining of the lateral ventricles: insights into the cause of periventricular heterotopia.	FLNA ARFGEF2	4.20e-05	2	226	2	16320251
Pubmed	Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS.	DMD NOS1	4.20e-05	2	226	2	22952904
Pubmed	The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.	PKD1 PKHD1	4.20e-05	2	226	2	11919560
Pubmed	Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling.	PTPN6 NOS1	4.20e-05	2	226	2	11511520
Pubmed	Variable phenotype of del45-55 Becker patients correlated with nNOSμ mislocalization and RYR1 hypernitrosylation.	RYR1 NOS1	4.20e-05	2	226	2	22589245
Pubmed	Survey of cancer cell anatomy in nonadhesive confinement reveals a role for filamin-A and fascin-1 in leader bleb-based migration.	FLNA FSCN1	4.20e-05	2	226	2	34260278
Pubmed	Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion.	RYR1 RYR2	4.20e-05	2	226	2	15033925
Pubmed	Myeloid cell-mediated targeting of LIF to dystrophic muscle causes transient increases in muscle fiber lesions by disrupting the recruitment and dispersion of macrophages in muscle.	DMD LIF	4.20e-05	2	226	2	34392367
Pubmed	Sarcolemmal targeting of nNOSμ improves contractile function of mdx muscle.	DMD NOS1	4.20e-05	2	226	2	26604149
Pubmed	Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.	PKD1 SIRT1	4.20e-05	2	226	2	23778143
Pubmed	Structural Basis of Neuronal Nitric-oxide Synthase Interaction with Dystrophin Repeats 16 and 17.	DMD NOS1	4.20e-05	2	226	2	26378238
Pubmed	An evolutionary conserved COUP-TF binding element in a neural-specific gene and COUP-TF expression patterns support a major role for COUP-TF in neural development.	NR2F1 NR2F2	4.20e-05	2	226	2	7708064
Pubmed	Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium.	DMD NOS1	4.20e-05	2	226	2	15917272
Pubmed	Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of duchenne muscular dystrophy.	DMD SIRT1	4.20e-05	2	226	2	25032964
Pubmed	Leukemia inhibitory factor induces multi-lineage differentiation of adult stem-like cells in kidney via kidney-specific cadherin 16.	LIF CDH16	4.20e-05	2	226	2	15670782
Pubmed	Spatiotemporal expression patterns of chicken ovalbumin upstream promoter-transcription factors in the developing mouse central nervous system: evidence for a role in segmental patterning of the diencephalon.	NR2F1 NR2F2	4.20e-05	2	226	2	8183930
Pubmed	Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state.	DMD NOS1	4.20e-05	2	226	2	9879685
Pubmed	Dynamic expression of COUP-TFI and COUP-TFII during development and functional maturation of the mouse inner ear.	NR2F1 NR2F2	4.20e-05	2	226	2	15907456
Pubmed	MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway.	DMD NOS1	4.20e-05	2	226	2	20727829
Pubmed	Expression and regulation of carnitine palmitoyltransferase-Ialpha and -Ibeta genes.	CPT1A CPT1B	4.20e-05	2	226	2	10408760
Pubmed	A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells.	DMD NOS1	4.20e-05	2	226	2	10793157
Pubmed	Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells.	TAOK2 TAOK1	4.20e-05	2	226	2	28830982
Pubmed	SIRT1 gene expression upon genotoxic damage is regulated by APE1 through nCaRE-promoter elements.	APEX1 SIRT1	4.20e-05	2	226	2	24356447
Pubmed	The Transcription Factors COUP-TFI and COUP-TFII have Distinct Roles in Arealisation and GABAergic Interneuron Specification in the Early Human Fetal Telencephalon.	NR2F1 NR2F2	4.20e-05	2	226	2	28922831
Pubmed	Nanoscale remodeling of ryanodine receptor cluster size underlies cerebral microvascular dysfunction in Duchenne muscular dystrophy.	RYR2 DMD	4.20e-05	2	226	2	30181262
Pubmed	Crystal structures of wild type and disease mutant forms of the ryanodine receptor SPRY2 domain.	RYR1 RYR2	4.20e-05	2	226	2	25370123
Pubmed	Optimization of Internally Deleted Dystrophin Constructs.	DMD NOS1	4.20e-05	2	226	2	27477497
Pubmed	Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis.	CPT1A CPT1B	4.20e-05	2	226	2	9013572
Pubmed	COUP-TFI and -TFII nuclear receptors are expressed in amacrine cells and play roles in regulating the differentiation of retinal progenitor cells.	NR2F1 NR2F2	4.20e-05	2	226	2	19766631
Pubmed	A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.	DMD NOS1	4.20e-05	2	226	2	11581289
Pubmed	Novel NR2F1 variants likely disrupt DNA binding: molecular modeling in two cases, review of published cases, genotype-phenotype correlation, and phenotypic expansion of the Bosch-Boonstra-Schaaf optic atrophy syndrome.	NR2F1 NR2F2	4.20e-05	2	226	2	28963436
Pubmed	Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection.	DMD NOS1	4.20e-05	2	226	2	11717466
Pubmed	Skeletal and cardiac ryanodine receptors exhibit different responses to Ca2+ overload and luminal ca2+.	RYR1 RYR2	4.20e-05	2	226	2	17259277
Pubmed	Structure and Function of the Human Ryanodine Receptors and Their Association with Myopathies-Present State, Challenges, and Perspectives.	RYR1 RYR2	4.20e-05	2	226	2	32899693
Pubmed	Circadian transcription factor NPAS2 and the NAD+ -dependent deacetylase SIRT1 interact in the mouse nucleus accumbens and regulate reward.	NPAS2 SIRT1	4.20e-05	2	226	2	35001440
Pubmed	Nitric oxide generated by muscle corrects defects in hippocampal neurogenesis and neural differentiation caused by muscular dystrophy.	DMD NOS1	4.20e-05	2	226	2	19237426
Pubmed	Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.	DMD NOS1	4.20e-05	2	226	2	7545544
Pubmed	Cardioprotective mIGF-1/SIRT1 signaling induces hypertension, leukocytosis and fear response in mice.	SIRT1 IGF1R	4.20e-05	2	226	2	22691943
Pubmed	Fine chromosome mapping of the genes for human liver and muscle carnitine palmitoyltransferase I (CPT1A and CPT1B).	CPT1A CPT1B	4.20e-05	2	226	2	9070950
Pubmed	The decrease of expression of ryanodine receptor sub-type 2 is reversed by gentamycin sulphate in vascular myocytes from mdx mice.	RYR2 DMD	4.20e-05	2	226	2	19298530
Pubmed	Role of defective calcium regulation in cardiorespiratory dysfunction in Huntington's disease.	RYR2 HTT	4.20e-05	2	226	2	32897880
Pubmed	Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy.	DMD NOS1	4.20e-05	2	226	2	8799168
Pubmed	Region-specific alterations in insulin-like growth factor-I receptor in the central nervous system of nNOS knockout mice.	NOS1 IGF1R	4.20e-05	2	226	2	15328041
Pubmed	Chicken ovalbumin upstream promoter transcription factor (COUP-TF): expression during mouse embryogenesis.	NR2F1 NR2F2	4.20e-05	2	226	2	7626501
Pubmed	Pathogenicity analysis of novel variations in Chinese Han patients with polycystic kidney disease.	PKD1 PKHD1	4.20e-05	2	226	2	28578020
Pubmed	Requirement for COUP-TFI and II in the temporal specification of neural stem cells in CNS development.	NR2F1 NR2F2	4.20e-05	2	226	2	19160499
Pubmed	All-trans retinoic acid affects the expression of orphan receptors COUP-TF I and COUP-TF II in the developing neural tube.	NR2F1 NR2F2	4.20e-05	2	226	2	8804707
Pubmed	Recent advances in understanding the ryanodine receptor calcium release channels and their role in calcium signalling.	RYR1 RYR2	4.20e-05	2	226	2	30542613
Pubmed	Ryanodine receptors are expressed and functionally active in mouse spermatogenic cells and their inhibition interferes with spermatogonial differentiation.	RYR1 RYR2	4.20e-05	2	226	2	15280431
Pubmed	Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.	USP9X USP24	4.20e-05	2	226	2	25814533
Pubmed	Expression of the ryanodine receptor isoforms in immune cells.	RYR1 RYR2	4.20e-05	2	226	2	11673493
Pubmed	B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.	RYR1 RYR2	4.20e-05	2	226	2	11673462
Pubmed	Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy.	DMD NOS1	4.20e-05	2	226	2	19542095
Pubmed	Thermodynamics of calmodulin binding to cardiac and skeletal muscle ryanodine receptor ion channels.	RYR1 RYR2	4.20e-05	2	226	2	18618700
Pubmed	Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.	DMD NOS1	4.20e-05	2	226	2	25214536
Pubmed	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.	PREX1 IGF1R	4.20e-05	2	226	2	23899556
Pubmed	Proteomic and Biochemical Comparison of the Cellular Interaction Partners of Human VPS33A and VPS33B.	VPS11 RREB1 TRAFD1 TELO2 BOP1 NUDT19 NRBF2 PHLDB2 KIF1C	4.27e-05	251	226	9	29778605
Pubmed	Loss of Fgfr3 leads to excess hair cell development in the mouse organ of Corti.	SPRY2 MYO7A FGFR3	4.30e-05	11	226	3	17117437
Pubmed	A High-Density Human Mitochondrial Proximity Interaction Network.	PDXDC1 SCYL1 MDN1 PMPCA TELO2 EHMT2 BOP1 VCPIP1 NUDT19 PDSS2 SYNE1 POLG UBR4 ZDBF2 NUDT16L1 FASTKD2 RHOT2 BRMS1L SIRT1 YARS2 CRYZ NISCH WDR12 CPSF7	4.64e-05	1496	226	24	32877691
Pubmed	Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation.	ZNF136 OBSCN TAOK2 EHMT2 PIGX HACE1 TONSL PKD1 PRMT2 SIPA1L2 TICRR NDST2 USP24 NSD1 LIF CRYZ IGF1R MROH1 MAP4K5 VCAN IL17RD	4.98e-05	1215	226	21	15146197
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	ZEB2 PRDM10 UBA7 MDN1 A2ML1 UBR4 FRMPD1 SAP30L BRMS1L RFX3 NR2F1 NR2F2 KMT2D ZFHX4 NISCH ANKRD17 CDC27	5.12e-05	857	226	17	25609649
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	RREB1 TRAFD1 MDN1 TAOK1 VCPIP1 FLNA USP24 SAP30L ARFGEF2 BRD3 VIRMA SIRT1 OSBP KMT2D ANKRD17 PHLDB2	5.27e-05	774	226	16	15302935
Pubmed	Single-cell transcriptomic analysis reveals diversity within mammalian spinal motor neurons.	B3GLCT NR2F1 NR2F2 ZFHX4	5.41e-05	32	226	4	36596814
Pubmed	Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.	RIN3 MYLK RYR1 EHMT2 PKD1 SNX8 FLNA MYRIP MAP4K5 CDC27	6.48e-05	329	226	10	17474147
Interaction	NPTN interactions	DOCK4 C17orf75 MDN1 TELO2 TONSL WDR35 COG4 PDSS2 USP24 ARFGEF2 CPT1A INTS8 ANKRD44 MROH1 HTT TEDC1	8.96e-08	278	223	16	int:NPTN
Interaction	TOP3B interactions	USP34 SPRY2 RIN3 MYO7A OBSCN RYR1 TAOK2 CDR2L MDN1 PKD1 SNX8 ZC3H7B SIPA1L2 CHPF SCARA3 PREX1 IQGAP3 DOC2A NUDT19 FLNA POLG UBR4 NSD1 AKNA ARFGEF2 RHOT2 NR2F2 KMT2D IGF1R AATK MROH1 DNAJC14 NISCH ANKRD17 IL17RD ARHGAP33 HTT	2.11e-06	1470	223	37	int:TOP3B
GeneFamily	Ankyrin repeat domain containing	ANKRD36C EHMT2 ANKAR HACE1 TONSL ANKRD50 ANKRD36B ANKRD44 ANKEF1 ANKRD17	7.43e-05	242	164	10	403
GeneFamily	A-kinase anchoring proteins\|Myosins, class VII\|Deafness associated genes\|FERM domain containing	MYO7A MYO7B	8.18e-05	2	164	2	1102
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR1 RYR2	2.44e-04	3	164	2	287
GeneFamily	Dyneins, axonemal	DNAH8 DNAH2 DNAH1	4.54e-04	17	164	3	536
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	MYO7A MYO7B FRMPD1 FRMD5	1.09e-03	50	164	4	1293
GeneFamily	Olfactory receptors, family 3	OR3A3 OR3A2	1.20e-03	6	164	2	150
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	F13B SRPX VCAN MASP2	1.77e-03	57	164	4	1179
GeneFamily	Zinc fingers MYND-type\|A-kinase anchoring proteins	MYO7A MYRIP ARFGEF2	2.25e-03	29	164	3	396
GeneFamily	WD repeat domain containing	WDR81 FBXW2 EML5 WDR35 BOP1 WDR7 WDR12 CFAP44	2.74e-03	262	164	8	362
GeneFamily	Zinc fingers C2H2-type\|Lysine methyltransferases\|PR/SET domain family	EHMT2 NSD1 KMT2D	3.57e-03	34	164	3	487
Coexpression	MARTINEZ_TP53_TARGETS_DN	SCYL1 RYR1 PKD1 TAOK1 DMD SCARA3 CERS4 FLNA POLG BRD3 FASTKD2 CPT1A VIRMA NR2F1 TIMP3 ETHE1 WDR12 KRT36 ACSL5 KIF1C	4.09e-07	615	225	20	M8673
Coexpression	MARTINEZ_TP53_TARGETS_DN	SCYL1 RYR1 PKD1 TAOK1 DMD SCARA3 CERS4 FLNA POLG BRD3 FASTKD2 CPT1A VIRMA NR2F1 TIMP3 ETHE1 WDR12 KRT36 ACSL5 KIF1C	1.19e-06	659	225	20	MM1040
Coexpression	MARTINEZ_RB1_AND_TP53_TARGETS_DN	SCYL1 RYR1 PKD1 TAOK1 DMD SCARA3 CERS4 FLNA POLG BRD3 FASTKD2 CPT1A NR2F1 TIMP3 ETHE1 WDR12 KRT36 ACSL5 KIF1C	1.53e-06	610	225	19	M3854
Coexpression	MARTINEZ_RB1_AND_TP53_TARGETS_DN	SCYL1 RYR1 PKD1 TAOK1 DMD SCARA3 CERS4 FLNA POLG BRD3 FASTKD2 CPT1A NR2F1 TIMP3 ETHE1 WDR12 KRT36 ACSL5 KIF1C	3.84e-06	650	225	19	MM1042
Coexpression	GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP	NMRAL1 PTPN6 PREX1 CERS4 PLA2G4E TTC7A LIF FSCN1 ACSL5 TEDC1	9.66e-06	200	225	10	M10032
Coexpression	GSE14308_TH17_VS_NATURAL_TREG_DN	DMD DNAH8 UVSSA NDST2 AKNA SIRT1 ANKRD44 KMT2D FBXO31	6.15e-05	200	225	9	M3390
Coexpression	GSE21546_WT_VS_SAP1A_KO_AND_ELK1_KO_DP_THYMOCYTES_DN	NRIP1 MYLK PKD1 PREX1 CERS4 ANKRD50 ATP8B2 SEMA3D ABCG1	6.15e-05	200	225	9	M7518
Coexpression	GSE17721_PAM3CSK4_VS_CPG_1H_BMDC_UP	MYO7A WDR81 POF1B DNAH8 NUDT19 CPT1A OSBP WDR12 ACSL5	6.15e-05	200	225	9	M3852
Coexpression	IKEDA_MIR30_TARGETS_UP	USP34 NRIP1 MAN1A2 TAOK1 DMD NRBF2 WDR7	6.60e-05	116	225	7	M2379
Coexpression	GSE36891_UNSTIM_VS_PAM_TLR2_STIM_PERITONEAL_MACROPHAGE_DN	SCYL1 PTPN6 PRDM10 BOP1 C9 BRD3 ABCG1 KIF1C	6.65e-05	157	225	8	M8788
Coexpression	MENON_FETAL_KIDNEY_3_STROMAL_CELLS	MYLK ZEB2 NR2F1 NR2F2 VCAN MACF1	7.10e-05	81	225	6	M39253
ToppCell	Control_saline-Mesenchymal_fibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	DOCK4 MYLK MYO7A ZEB2 SRPX SYNE1 NR2F1 NR2F2 SEMA3D VCAN MACF1	7.12e-09	200	227	11	64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts\|Control_saline / Treatment groups by lineage, cell group, cell type	DOCK4 MYLK MYO7A ZEB2 SRPX SYNE1 NR2F1 NR2F2 SEMA3D VCAN MACF1	7.12e-09	200	227	11	a1fc74c1b27e104895910bc7cdce7ba33d30df7e
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	USP34 USP9X ANKRD36C ZEB2 TAOK1 USP24 EPG5 ANKRD44 MACF1 RORA	4.77e-08	188	227	10	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	severe-low-quality_cells\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	ANKRD36C IFI44L SYNE1 USP24 AKNA RFX3 ANKRD44 MACF1 RORA MASP2	6.11e-08	193	227	10	9337bc93e3904c7fc7c93c328518bcd6453b1e8c
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DOCK4 MYLK RYR2 TBX4 NR2F1 NR2F2 TIMP3 MACF1 RORA PHLDB2	6.11e-08	193	227	10	b3ad5ff480d99217f36cc7471e5a96a519ddb409
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DOCK4 DCBLD1 ZEB2 TBX4 NR2F1 NR2F2 ZFHX4 VCAN MACF1 RORA	6.42e-08	194	227	10	b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	MYLK DCBLD1 ZEB2 TBX4 NR2F1 NR2F2 ZFHX4 VCAN MACF1 RORA	6.73e-08	195	227	10	0e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	ANKRD36C ZEB2 SNX31 AKNA ANKRD44 KMT2D AATK MACF1 RORA	6.80e-08	147	227	9	94998bc40f5c08295cfe3bdcbe43f13b1e564b3d
ToppCell	Bronchial-NucSeq-Stromal-Peri/Epineurial_-NAF_endoneurial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MYO7A PKHD1 IFI44L SCARA3 DOC2A ZDBF2 NR2F2 VCAN FSCN1 IL17RD	7.41e-08	197	227	10	6806ec223e542f0475303698eb78c1cc527f5c6b
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	DOCK4 MYLK ZEB2 SRPX SYNE1 NR2F1 NR2F2 SEMA3D VCAN MACF1	8.15e-08	199	227	10	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_3\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK POPDC2 ARHGEF17 ZEB2 RYR2 DMD FLNA SYNE1 NR2F2 GUCY1B1	8.54e-08	200	227	10	b0866b497aa71d06cef25f9a335fa584e95fa7e0
ToppCell	Control_saline-Mesenchymal_myocytic\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 RYR2 DMD SCARA3 FLNA SYNE1 NR2F2 VCAN	8.54e-08	200	227	10	5ed4261157cd51109b314818133ac3a0d34ee5fa
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SPRY2 MYLK ZEB2 SRPX TBX4 SYNE1 NR2F1 TIMP3 VCAN PHLDB2	8.54e-08	200	227	10	3dd022e974fec7013ba18f333da63f58fbf2dd7c
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	DOCK4 MYLK ZEB2 SRPX SYNE1 NR2F1 NR2F2 SEMA3D VCAN MACF1	8.54e-08	200	227	10	bd8cf33502adea320e91ca2af14e1911d88ad374
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TSNAXIP1 LRGUK DNAH2 DNAH1 ADGB RAB36 ANKEF1 HEATR9 CFAP44	1.07e-07	155	227	9	5f1e2195a6b831e1b636f5cc3a282ca423721822
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TSNAXIP1 LRGUK DNAH2 DNAH1 ADGB RAB36 ANKEF1 HEATR9 CFAP44	1.07e-07	155	227	9	0944429459f642a1bcc56edc1ec28aaecde3e2dc
ToppCell	ICU-NoSEP-Lymphocyte-T_NK-NK_CD56bright\|ICU-NoSEP / Disease, Lineage and Cell Type	SPRY2 C5orf34 HACE1 RASGEF1A NLRP2 OSBP SH2D1B ANKEF1 ZNF639	2.03e-07	167	227	9	f4f188a8efca8cdd0ecfb857fe4538c10847eadd
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HECW1 MYO7B OBSCN RYR2 PKHD1 DMD DNAH1 ZFHX4 MYH15	4.60e-07	184	227	9	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGEF17 RYR2 SRPX DMD TRABD2A TBX4 NR2F1 NR2F2 GUCY1B1	4.60e-07	184	227	9	689a8af81a79a4bb3123cfa01958c953eab5de98
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HECW1 MYO7B OBSCN RYR2 PKHD1 DMD DNAH1 ZFHX4 MYH15	4.60e-07	184	227	9	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HECW1 MYO7B OBSCN RYR2 PKHD1 DMD DNAH1 ZFHX4 MYH15	4.60e-07	184	227	9	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYLK OBSCN ARHGEF17 RYR2 DMD TBX4 NR2F1 NR2F2 GUCY1B1	5.03e-07	186	227	9	888e85a025bd982d36c910db0f5a3385b1ca3b28
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYLK RYR2 DMD SCARA3 TBX4 SYNE1 NR2F1 NR2F2 SEMA3D	7.16e-07	194	227	9	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	MYLK ZEB2 TBX4 NR2F1 NR2F2 SEMA3D VCAN MACF1 RORA	7.48e-07	195	227	9	1cdf5f296029ae424d9dba42e86a6d111e4896e6
ToppCell	severe-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	USP34 ANKRD36C SYNE1 USP24 ZDBF2 RFX3 ANKRD44 MACF1 RORA	8.14e-07	197	227	9	57ebd552f10d6278623b52a3d484d4b91ae1d028
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TSNAXIP1 LRGUK DMD DOC2A SYNE1 DNAH2 RFX3 ADGB CFAP44	8.14e-07	197	227	9	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	LPS_only-Epithelial_airway-airway_epithelial-Ciliated\|LPS_only / Treatment groups by lineage, cell group, cell type	TSNAXIP1 MYO7A EML5 WDR35 DNAH1 ADGB RAB36 CFAP44 ARHGAP33	8.49e-07	198	227	9	6d90b541fde357fbb40f8f7d4e8628a48b679718
ToppCell	Control-Control-Lymphocyte-T/NK-NK_activated\|Control / Disease, condition lineage and cell class	IFI44L NPAS2 DOC2A FLNA SYNE1 AKNA SH2D1B MACF1 FRMD5	8.49e-07	198	227	9	76d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	USP34 ANKRD36C IFI44L SYNE1 USP24 AKNA ANKRD44 MACF1 RORA	8.85e-07	199	227	9	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK ZEB2 RYR2 DMD SCARA3 FLNA SYNE1 SEMA3D VCAN	9.23e-07	200	227	9	9d5b3c2dcfa55d50acc2ce2c319d51aa525d4cd1
ToppCell	Sepsis-ICU-NoSEP-Lymphocyte-T/NK-NK_CD56bright\|ICU-NoSEP / Disease, condition lineage and cell class	SPRY2 C5orf34 HACE1 RASGEF1A NLRP2 OSBP SH2D1B ANKEF1 ZNF639	9.23e-07	200	227	9	c2df917900872453ea17a39928e39d071a6d3339
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_2\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 RYR2 SRPX ANKRD50 NR2F2 GUCY1B1 LRRC8B	9.23e-07	200	227	9	bc8949eb34482aca166c4602ff6ab876cb4c2c3c
ToppCell	LPS_IL1RA_TNF-Epithelial_airway\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	TSNAXIP1 POF1B A2ML1 DNAH2 DNAH1 ADGB LIF HEATR9 CFAP44	9.23e-07	200	227	9	72c1d9eeaed4b3ee6b6c602e8aa29efc2e8744eb
ToppCell	LPS_IL1RA_TNF-Epithelial_airway-airway_epithelial\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	TSNAXIP1 POF1B A2ML1 DNAH2 DNAH1 ADGB LIF HEATR9 CFAP44	9.23e-07	200	227	9	da12821e8a0657869ca0f75d351cce2d7605a505
ToppCell	LPS_IL1RA-Mesenchymal_myocytic-Pericyte\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 SRPX DMD FLNA SYNE1 NR2F2 GUCY1B1	9.23e-07	200	227	9	b22cae282591d8dead9869c2adbb9632615f50f7
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	MYLK ZEB2 SRPX SYNE1 NR2F1 NR2F2 SEMA3D VCAN MACF1	9.23e-07	200	227	9	44a68bacdb3d5bf563bd35952176995850933a81
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 RYR2 DMD SCARA3 FLNA SYNE1 NR2F2	9.23e-07	200	227	9	67dcbd86fbc79fd585d0793f979e4aac100326c9
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	MYLK ZEB2 SRPX SYNE1 NR2F1 NR2F2 SEMA3D VCAN MACF1	9.23e-07	200	227	9	dc61016c61729f69649cfb21f6264e685ce83dea
ToppCell	LPS_only-Mesenchymal_myocytic\|LPS_only / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 RYR2 DMD SCARA3 FLNA SYNE1 NR2F2	9.23e-07	200	227	9	8bc9923f82bfb836e2f524204c92050edeae8ca5
ToppCell	LPS_IL1RA-Mesenchymal_myocytic\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 SRPX DMD SCARA3 FLNA SYNE1 NR2F2	9.23e-07	200	227	9	77631c471cc5d453a749784f838cfa6408caf09b
ToppCell	10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	USP34 ANKRD36C TRABD2A ATP8B2 ANKRD36B ANKRD44 MACF1 RORA	1.88e-06	162	227	8	b4535bcb3f469bc139e73f1122f4070013e5a1de
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC-ASMC_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYLK ATP8A2 POPDC2 MYBPHL RAPSN ZFHX4 SLC47A1 FRMD5	3.49e-06	176	227	8	4ed73c73972334f6dc4229920205547823252fa0
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c05-FOS\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	EVC PRDM10 COG4 CPT1B INTS8 DNAH1 DNAJC14	4.50e-06	129	227	7	2f30b4897343586c9b49a1d2bec3007ec737085c
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYLK ARHGEF17 SRPX DMD TRABD2A TBX4 NR2F1 NR2F2	4.84e-06	184	227	8	102b6f621a5b551e622f97b12d787c080b052a72
ToppCell	367C-Endothelial_cells-Endothelial-B_(Artery)-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	MYO7B POPDC2 UMODL1 SRPX SIPA1L2 NOS1 TRABD2A AATK	5.04e-06	185	227	8	b57dae20c21f984edd2acee4344d86f033108ebf
ToppCell	NS-moderate-d_16-33-Epithelial-Ciliated\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	TSNAXIP1 LRGUK LRRC34 DNAH2 ADGB RAB36 AGBL2 CFAP44	5.04e-06	185	227	8	5e689c2fb36ce3ac2adc8d15f67107f21cf68868
ToppCell	367C-Endothelial_cells-Endothelial-B_(Artery)\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	MYO7B POPDC2 UMODL1 SRPX SIPA1L2 NOS1 TRABD2A AATK	5.04e-06	185	227	8	d3b054d203e575c1bb5455aa7a2e551a0957a760
ToppCell	facs-Heart-LA/RA-3m-Mesenchymal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN NTSR2 POPDC2 RYR2 MYBPHL CPT1B SLC47A1 FRMD5	5.67e-06	188	227	8	90dc0e15798d0b984518ad58c7e416e30aff687a
ToppCell	facs-Heart-LA/RA-3m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN NTSR2 POPDC2 RYR2 MYBPHL CPT1B SLC47A1 FRMD5	5.67e-06	188	227	8	f63dfd076ced81013918363282ae25cbbd8948ae
ToppCell	facs-Heart-LA/RA-3m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN NTSR2 POPDC2 RYR2 MYBPHL CPT1B SLC47A1 FRMD5	5.67e-06	188	227	8	0554d542149cef654ff1e5e32dfbffd8990b52bd
ToppCell	facs-Heart-LA/RA-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN NTSR2 POPDC2 RYR2 MYBPHL CPT1B SLC47A1 FRMD5	5.90e-06	189	227	8	a08b2d0fa35ffa510050ecffdc68e1b79bbe1632
ToppCell	facs-Heart-RA-24m-Mesenchymal-ventricular_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NTSR2 RYR2 MYBPHL RAPSN CPT1B PLA2G4E SLC47A1 FRMD5	5.90e-06	189	227	8	b98f60875b1a12b2ec9dc91889298ae57f98602f
ToppCell	facs-Heart-LA/RA\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN NTSR2 POPDC2 RYR2 MYBPHL CPT1B SLC47A1 FRMD5	5.90e-06	189	227	8	efa913d9c16fc32166b484d92b6449e8a0c59e03
ToppCell	facs-Heart-RA-24m-Mesenchymal-ventricular_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NTSR2 RYR2 MYBPHL RAPSN CPT1B PLA2G4E SLC47A1 FRMD5	5.90e-06	189	227	8	e758b264c0a47127e33e66c395cf5a3224c7305b
ToppCell	E18.5-samps-Mesenchymal\|E18.5-samps / Age Group, Lineage, Cell class and subclass	MYLK ZEB2 FLNA TBX4 NR2F2 GUCY1B1 VCAN MACF1	5.90e-06	189	227	8	0c18d3de4720759cf802eefb4d0ddde2a9246a1a
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.4.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ZEB2 PRMT2 SYNE1 AKNA ANKRD36B ANKRD44 MACF1 RORA	6.13e-06	190	227	8	d153a0bdedcd6865e6ee19575234a78b5d859ff1
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYLK OBSCN ARHGEF17 RYR2 TBX4 NR2F1 NR2F2 GUCY1B1	6.37e-06	191	227	8	1626b23a57429f835fddc052e3c57f63a4e5b8bb
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Lung_smooth_muscle\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYLK ARHGEF17 RYR2 DMD SCARA3 TBX4 SYNE1 NR2F2	6.37e-06	191	227	8	7853ac7dff649150e6ff27cd4c8cf7c1fc034ed4
ToppCell	PND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	DOCK4 MYLK RREB1 ARHGEF17 FGFR3 TBX4 NR2F2 MACF1	6.37e-06	191	227	8	e7c605b56934d1383237c1f946dbccef25d91368
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYLK OBSCN ARHGEF17 RYR2 TBX4 NR2F1 NR2F2 GUCY1B1	6.37e-06	191	227	8	716dfa7fccbd62b5f574792e68a26dc6c45511dc
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYLK ZEB2 RYR2 DMD SCARA3 FLNA TBX4 NR2F2	6.62e-06	192	227	8	992d08092edbc68c47b945deb8708379738c239a
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DOCK4 MYLK RYR2 TBX4 NR2F1 TIMP3 MACF1 RORA	6.87e-06	193	227	8	99525545552b371c86b18b6ea6f4897dc6e9a9ec
ToppCell	Control_saline-Epithelial_airway-airway_epithelial-Ciliated\|Control_saline / Treatment groups by lineage, cell group, cell type	TSNAXIP1 UMODL1 DNAH2 DNAH1 ADGB RAB36 HEATR9 CFAP44	7.41e-06	195	227	8	60067b5359174f0d1a8b5748bfc0690762e9e740
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	HECW1 ATP8A2 RYR2 MAN1A2 PKD1 SYNE1 MYRIP ANKRD36B	7.69e-06	196	227	8	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DOCK4 MYLK ZEB2 NR2F1 SEMA3D VCAN MACF1 RORA	7.69e-06	196	227	8	1450cb69c5bf469e97c03bf1890f6f7c54165b8a
ToppCell	COVID-19-lung-Pericytes/_Smooth_Muscle\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MYLK ARHGEF17 RYR2 DMD FLNA TBX4 NR2F2 GUCY1B1	7.69e-06	196	227	8	754a3613340932563cd8424d775e18b93c3a1aaa
ToppCell	Bronchial-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MYLK RYR2 DCLK2 SCARA3 FLNA TBX4 SEMA3D CDH16	7.69e-06	196	227	8	9830fb3da7a60f65ad463e9054bb77c06b025e4d
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK ARHGEF17 ZEB2 FLNA NR2F1 NR2F2 TIMP3 GUCY1B1	7.69e-06	196	227	8	ebac1d6af7a5732707d82d01285c086b19d8ae62
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK ZEB2 DCLK2 DMD FLNA NR2F1 NR2F2 VCAN	7.69e-06	196	227	8	fa445f4240c521cf04eb2e2f79a5c55fda31209a
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK ZEB2 DCLK2 DMD FLNA NR2F1 NR2F2 VCAN	7.69e-06	196	227	8	802f61e78a9a1030a86c4a980c398a73cd4d1574
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK ARHGEF17 ZEB2 FLNA NR2F1 NR2F2 TIMP3 GUCY1B1	7.69e-06	196	227	8	5146976881d79642ebe5dcbcf89e0252713a9ef2
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK ARHGEF17 ZEB2 FLNA NR2F1 NR2F2 TIMP3 GUCY1B1	7.98e-06	197	227	8	d14e1f2ba94240c61eac435db43508a224d606a8
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DOCK4 MYLK ZEB2 NR2F1 SEMA3D VCAN MACF1 RORA	7.98e-06	197	227	8	31a1852911bda38543916585fda34255fd62a134
ToppCell	PCW_13-14-Mesenchymal\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	MYLK ZEB2 TBX4 NR2F1 NR2F2 SEMA3D VCAN RORA	7.98e-06	197	227	8	73a2085d2682d636726a5432d572ae2a3fbe1c3f
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	MYLK ZEB2 SRPX NR2F1 NR2F2 SEMA3D VCAN MACF1	8.28e-06	198	227	8	0a4b19c3d5e65ecd24fc2ce80ac5276c813282c7
ToppCell	Control_saline-Epithelial_airway\|Control_saline / Treatment groups by lineage, cell group, cell type	TSNAXIP1 POF1B DNAH2 DNAH1 ADGB RAB36 HEATR9 CFAP44	8.28e-06	198	227	8	e6863238e022ecfb6a8e3f4b7661b376e92c5d8f
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Mesenchymal\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK ARHGEF17 ZEB2 FLNA NR2F1 NR2F2 TIMP3 GUCY1B1	8.28e-06	198	227	8	54c8aa47040bc4977eed382514fc4ceae03f54f8
ToppCell	Fetal_29-31_weeks-Mesenchymal\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MYLK RYR2 TBX4 NR2F1 NR2F2 SEMA3D VCAN RORA	8.28e-06	198	227	8	21cf4d81386761d09d0f6829c01c198e5524176d
ToppCell	Control_saline-Epithelial_airway-airway_epithelial\|Control_saline / Treatment groups by lineage, cell group, cell type	TSNAXIP1 POF1B DNAH2 DNAH1 ADGB RAB36 HEATR9 CFAP44	8.28e-06	198	227	8	e7aa42e5fbd42c68f50cda4a8f3aa464c862c007
ToppCell	E18.5-Mesenchymal\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYLK ZEB2 FLNA TBX4 NR2F2 GUCY1B1 VCAN MACF1	8.28e-06	198	227	8	a16aa41eab2e297e56de43c22c355df0f79315da
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYLK RYR2 SCARA3 SYNE1 NR2F1 NR2F2 VCAN MACF1	8.59e-06	199	227	8	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	LPS_anti-TNF-Epithelial_airway-airway_epithelial-Ciliated\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	TSNAXIP1 LRGUK DNAH2 DNAH1 ADGB RAB36 HEATR9 CFAP44	8.59e-06	199	227	8	15f7814b7074170eee7ccacaa670b1d128fc68bb
ToppCell	PCW_10-12-Mesenchymal\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	MYLK ZEB2 TBX4 NR2F1 NR2F2 SEMA3D VCAN RORA	8.59e-06	199	227	8	a09292de4c4447b8eee55d401808e43b817321cc
ToppCell	Control_saline-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK ZEB2 RYR2 DMD SCARA3 FLNA SYNE1 SEMA3D	8.91e-06	200	227	8	c5e051f1aac8dda376c342a9932785a23450e073
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Smooth_muscle-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	MYLK OBSCN ARHGEF17 RYR2 DMD TBX4 NR2F1 NR2F2	8.91e-06	200	227	8	0c648941447c738caf62f2d71e296d6cca492c8b
ToppCell	LPS_IL1RA_TNF-Mesenchymal_myocytic\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 DMD SCARA3 FLNA SYNE1 NR2F2	8.91e-06	200	227	8	f599e4b051ac3dad11ad437e98dc8ea6754cca53
ToppCell	LPS_anti-TNF-Mesenchymal_myocytic-Pericyte\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 RYR2 SRPX DMD ANKRD50 NR2F2 GUCY1B1	8.91e-06	200	227	8	4e1e19214aeebbdca004de7faaf4cc9d18498591
ToppCell	LPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	MYLK POPDC2 ARHGEF17 RYR2 DMD FLNA SYNE1 NR2F2	8.91e-06	200	227	8	c06426f877919bdd267ea2fd7e7973c6619832ae
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Smooth_muscle-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MYLK OBSCN ARHGEF17 RYR2 DMD TBX4 NR2F1 NR2F2	8.91e-06	200	227	8	522a51a284d2992d519c4669e1a48c8ebcc08c80
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Smooth_muscle-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MYLK OBSCN ARHGEF17 RYR2 DMD TBX4 NR2F1 NR2F2	8.91e-06	200	227	8	94f1fa61aa82eb9f411b2b1cb759476939ab5db7
ToppCell	LPS_only-Mesenchymal_myocytic-Pericyte-Pericyte_3\|LPS_only / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 RYR2 DMD FLNA SYNE1 NR2F2 GUCY1B1	8.91e-06	200	227	8	7c62678cf408aaaf98d6df0fb27814d2007c4521
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MYLK HECW1 ZEB2 RYR2 TBX4 SYNE1 NR2F1 VCAN	8.91e-06	200	227	8	58b38f9a484ee94191091a0659ed62ebed2d4a14
ToppCell	LPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	MYLK ZEB2 RYR2 DMD SCARA3 FLNA SYNE1 SEMA3D	8.91e-06	200	227	8	8988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-5w-Mesenchymal-Mesoderm\|5w / Sample Type, Dataset, Time_group, and Cell type.	MYO7A C5orf34 AKNA ARFGEF2 RASGEF1A VIRMA PCIF1 ZNF639	8.91e-06	200	227	8	0927061536a664b4f7feb9e5b0a8c11ca0d5955c
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte\|Control_saline / Treatment groups by lineage, cell group, cell type	MYLK ARHGEF17 ZEB2 RYR2 SRPX FLNA NR2F2 GUCY1B1	8.91e-06	200	227	8	cb7ef774b6d300f8019c5b16a04e3ebd165e4f1c
ToppCell	LPS-IL1RA-Epithelial_airway-Ciliated_cells\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TSNAXIP1 LRGUK DNAH2 DNAH1 ADGB RAB36 ANKEF1	1.26e-05	151	227	7	81cf939ed4df9574fbfff265e109cb9f947d7e6e
ToppCell	LPS-IL1RA-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TSNAXIP1 LRGUK DNAH2 DNAH1 ADGB RAB36 ANKEF1	1.26e-05	151	227	7	9cbcbbc22965a9f0be8364e733d205dd64f2a533
ToppCell	LPS_only-Epithelial_airway-Ciliated_cells-Ciliated\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TSNAXIP1 DNAH1 ADGB RAB36 ANKEF1 HEATR9 CFAP44	1.44e-05	154	227	7	9ca71d440c4f87781e6525b8141e7d8d470b6a8e
ToppCell	LPS_only-Epithelial_airway-Ciliated_cells\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TSNAXIP1 DNAH1 ADGB RAB36 ANKEF1 HEATR9 CFAP44	1.44e-05	154	227	7	58072ce422d09f2de602580325eaac6c4ec6c136
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ARHGEF17 RYR2 DMD TRABD2A TBX4 NR2F1 NR2F2	1.56e-05	156	227	7	6365b69ede98bc866e996bc52736b00401aacf6f
Disease	free cholesterol:total lipids ratio, intermediate density lipoprotein measurement	PDXDC1 PMPCA RAPSN NRBF2 CPT1A MAP4K5 PCIF1	4.03e-06	86	222	7	EFO_0008595, EFO_0020945
Disease	susceptibility to mononucleosis measurement	RYR2 MDN1 DMD DNAH8 DNAH2 ANKRD50	1.37e-05	69	222	6	EFO_0008403
Disease	level of Sphingomyelin (d36:2) in blood serum	CERS4 RAPSN ANKRD17	1.44e-05	7	222	3	OBA_2045177
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	PDXDC1 PMPCA RAPSN CPT1A DNAH1 MAP4K5 PCIF1 MACF1 HTT	2.23e-05	200	222	9	EFO_0004611, EFO_0020945
Disease	Malignant neoplasm of breast	NRIP1 OBSCN PFKFB4 ZEB2 C5orf34 DMD FLNA SYNE1 UBR4 FRMPD1 ARFGEF2 CPT1A NR2F1 SIRT1 EPG5 KMT2D IGF1R NISCH ANKEF1 HEATR9 MACF1 CDC27	2.26e-05	1074	222	22	C0006142
Disease	total blood protein measurement	RREB1 PMPCA PKD1 SNX8 PKHD1 LRRC34 RAPSN DNAH1 KMT2D MAP4K5 MACF1 RORA LRRC8B	3.98e-05	449	222	13	EFO_0004536
Disease	Periventricular nodular heterotopia	FLNA ARFGEF2	5.64e-05	2	222	2	cv:C1868720
Disease	level of Sterol ester (27:1/20:5) in blood serum	NWD2 RAPSN CPT1A	6.63e-05	11	222	3	OBA_2045197
Disease	level of Sterol ester (27:1/20:4) in blood serum	PDXDC1 SCGB2A1 RAPSN CPT1A	8.37e-05	31	222	4	OBA_2045198
Disease	intracranial aneurysm (is_implicated_in)	PKD1 KMT2D VCAN	8.79e-05	12	222	3	DOID:10941 (is_implicated_in)
Disease	very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	PDXDC1 PMPCA RAPSN CPT1A MAP4K5 PCIF1 MACF1 FRMD5 HTT	8.88e-05	239	222	9	EFO_0008317, EFO_0020945
Disease	alkaline phosphatase measurement	USP34 RIN3 WDR81 EVC RREB1 NWD2 MAN1A2 TRAFD1 PMPCA TONSL PKD1 COG4 RAPSN NRBF2 CPT1A TTC7A MAP4K5 PCIF1 MACF1 FRMD5	9.16e-05	1015	222	20	EFO_0004533
Disease	dihomo-linolenoylcarnitine (C20:3n3 or 6) measurement	PDXDC1 RAPSN CPT1A	1.14e-04	13	222	3	EFO_0800547
Disease	triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement	PDXDC1 RAPSN CPT1A MAP4K5 PCIF1 MACF1 HTT	1.47e-04	150	222	7	EFO_0004611, EFO_0020947
Disease	triglycerides in very small VLDL measurement	EHMT2 RAPSN NRBF2 MAP4K5 PCIF1	1.63e-04	68	222	5	EFO_0022144
Disease	Ellis-Van Creveld syndrome (is_implicated_in)	EVC WDR35	1.68e-04	3	222	2	DOID:12714 (is_implicated_in)
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR1 RYR2	1.68e-04	3	222	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR1 RYR2	1.68e-04	3	222	2	DOID:8545 (implicated_via_orthology)
Disease	achalasia (implicated_via_orthology)	SPRY2 NOS1	1.68e-04	3	222	2	DOID:9164 (implicated_via_orthology)
Disease	1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) measurement	PDXDC1 RAPSN	1.68e-04	3	222	2	EFO_0800461
Disease	very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio	PDXDC1 PMPCA RAPSN USP24 CPT1A MAP4K5 PCIF1 MACF1 HTT	1.88e-04	264	222	9	EFO_0008317, EFO_0020944
Disease	degree of unsaturation measurement	PDXDC1 CPT1A MAP4K5 PCIF1	2.09e-04	39	222	4	EFO_0022261
Disease	bitter beverage consumption measurement	PFKFB4 ZNF568 MAP4K5 AGBL2	2.79e-04	42	222	4	EFO_0010089
Disease	very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio	PDXDC1 PMPCA USP24 CPT1A MAP4K5 PCIF1 MACF1 HTT	2.94e-04	222	222	8	EFO_0008317, EFO_0020943
Disease	monounsaturated fatty acids; 16:1, 18:1 measurement	PDXDC1 RAPSN CPT1A MAP4K5 PCIF1	3.11e-04	78	222	5	EFO_0022187
Disease	high density lipoprotein particle size measurement	PDXDC1 VPS11 RAPSN MAP4K5 NISCH PCIF1 AGBL2	3.16e-04	170	222	7	EFO_0008592
Disease	1-dihomo-linolenoyl-GPC (20:3n3 or 6) measurement	PDXDC1 RAPSN	3.35e-04	4	222	2	EFO_0800235
Disease	cerebellar ataxia, mental retardation and dysequlibrium syndrome (is_implicated_in)	ATP8A2 WDR81	3.35e-04	4	222	2	DOID:0050997 (is_implicated_in)
Disease	epilepsy (is_marker_for)	FLNA SIRT1	3.35e-04	4	222	2	DOID:1826 (is_marker_for)
Disease	level of Sphingomyelin (d38:2) in blood serum	CERS4 RAPSN ANKRD17	3.72e-04	19	222	3	OBA_2045179
Disease	level of Sterol ester (27:1/20:3) in blood serum	PDXDC1 RAPSN USP24	3.72e-04	19	222	3	OBA_2045199
Disease	very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio	PDXDC1 PMPCA RAPSN USP24 CPT1A MAP4K5 PCIF1 MACF1 HTT	3.84e-04	291	222	9	EFO_0008317, EFO_0020946
Disease	triacylglycerol 54:4 measurement	ATP8A2 PIGX RAPSN MAP4K5	3.97e-04	46	222	4	EFO_0010422
Disease	triglycerides:total lipids ratio, intermediate density lipoprotein measurement	PDXDC1 RAPSN CPT1A MAP4K5 PCIF1 MACF1	4.11e-04	127	222	6	EFO_0008595, EFO_0020947
Disease	QRS duration	PDXDC1 USP34 KCND3 CHPF NPAS2 NRBF2 UBR4 ANKRD50 IGF1R	4.56e-04	298	222	9	EFO_0005055
Disease	polyunsaturated fatty acids to total fatty acids percentage	PDXDC1 RAPSN CPT1A MAP4K5	5.48e-04	50	222	4	EFO_0022303
Disease	Malignant Cystosarcoma Phyllodes	FLNA KMT2D	5.55e-04	5	222	2	C0600066
Disease	sphingomyeline C18:1 measurement	CERS4 RAPSN	5.55e-04	5	222	2	EFO_0801320
Disease	Phyllodes Tumor	FLNA KMT2D	5.55e-04	5	222	2	C0010701
Disease	cerebellar ataxia (is_implicated_in)	SYNE1 POLG	5.55e-04	5	222	2	DOID:0050753 (is_implicated_in)
Disease	Duchenne muscular dystrophy (is_marker_for)	DMD NOS1	5.55e-04	5	222	2	DOID:11723 (is_marker_for)
Disease	Dysequilibrium syndrome	ATP8A2 WDR81	5.55e-04	5	222	2	C0394006
Disease	1-myristoyl-2-linoleoyl-GPC (14:0/18:2) measurement	RAPSN MAP4K5	5.55e-04	5	222	2	EFO_0800452
Disease	phosphatidylcholine (16:0/22:5n3, 18:1/20:4) measurement	RAPSN CPT1A	5.55e-04	5	222	2	EFO_0800467
Disease	1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) measurement	PDXDC1 RAPSN	5.55e-04	5	222	2	EFO_0800407
Disease	triglycerides to total lipids in large LDL percentage	PDXDC1 RAPSN MAP4K5 PCIF1	5.91e-04	51	222	4	EFO_0022331
Disease	polyunsaturated fatty acids to monounsaturated fatty acids ratio	PDXDC1 CPT1A MAP4K5 PCIF1	5.91e-04	51	222	4	EFO_0022302
Disease	free cholesterol to total lipids in small HDL percentage	PDXDC1 RAPSN CPT1A PCIF1	5.91e-04	51	222	4	EFO_0022285
Disease	Familial thoracic aortic aneurysm and aortic dissection	MYLK PKD1 FLNA VCAN	6.84e-04	53	222	4	C4707243
Disease	triglycerides to total lipids in very large VLDL percentage	PDXDC1 CPT1A MAP4K5 PCIF1	6.84e-04	53	222	4	EFO_0022340
Disease	colorectal cancer	RIN3 DCBLD1 RREB1 SNX31 NOS1 PREX1 B3GLCT RAPSN BRD3 BRMS1L VCAN MACF1 CFAP44	7.11e-04	604	222	13	MONDO_0005575
Disease	airway responsiveness measurement	PDSS2 USP24 MYH15	7.57e-04	24	222	3	EFO_0006897
Disease	cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement	PDXDC1 RAPSN CPT1A MAP4K5 PCIF1 MACF1	7.98e-04	144	222	6	EFO_0004611, EFO_0020943
Disease	Sphingomyelin (d18:1/20:1, d18:2/20:0) measurement	CERS4 RAPSN	8.29e-04	6	222	2	EFO_0022110
Disease	Sphingomyelin (d18:1/18:1, d18:2/18:0) measurement	CERS4 RAPSN	8.29e-04	6	222	2	EFO_0022108
Disease	quality of life during menstruation measurement, breast pressure measurement	DCLK2 ANKRD17	8.29e-04	6	222	2	EFO_0009366, EFO_0009393
Disease	MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE	RYR1 RAPSN	8.29e-04	6	222	2	C1854678
Disease	gondoic acid measurement	RAPSN MAP4K5	8.29e-04	6	222	2	EFO_0007975
Disease	Streptococcal pneumonia	SIRT1 MASP2	8.29e-04	6	222	2	C0155862
Disease	dihomo-linolenate 20:3n3 or n6 measurement	PDXDC1 RAPSN	8.29e-04	6	222	2	EFO_0021046
Disease	periventricular nodular heterotopia (is_implicated_in)	FLNA ARFGEF2	8.29e-04	6	222	2	DOID:0050454 (is_implicated_in)
Disease	1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) measurement	PDXDC1 RAPSN	8.29e-04	6	222	2	EFO_0800390
Disease	1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) measurement	PDXDC1 RAPSN	8.29e-04	6	222	2	EFO_0800434
Disease	1-dihomo-linolenoyl-GPE (20:3n3 or 6) measurement	PDXDC1 RAPSN	8.29e-04	6	222	2	EFO_0800358
Disease	cholesterol to total lipids in large LDL percentage	PDXDC1 RAPSN MAP4K5 PCIF1	8.43e-04	56	222	4	EFO_0022235
Disease	alpha-linolenic acid measurement	PDXDC1 RAPSN LCT	8.55e-04	25	222	3	EFO_0007759
Disease	white matter integrity, age at assessment	WDR7 VCAN WDR12	9.61e-04	26	222	3	EFO_0004641, EFO_0008007
Disease	obsessive-compulsive disorder, Tourette syndrome	HACE1 WDR7 GBA3	9.61e-04	26	222	3	EFO_0004242, EFO_0004895
Disease	cholesterol in chylomicrons and extremely large VLDL measurement	PDXDC1 EHMT2 RAPSN MAP4K5	1.09e-03	60	222	4	EFO_0021898
Disease	Cerebellar Diseases	ZEB2 NOS1	1.15e-03	7	222	2	C0007760
Disease	Periventricular Nodular Heterotopia	FLNA ARFGEF2	1.15e-03	7	222	2	C1868720
Disease	Alzheimer disease	HECW1 WDR81 CDR2L PKHD1 SIPA1L2 SCARA3 DOC2A SAP30L MYRIP MROH1 WDR12	1.20e-03	485	222	11	MONDO_0004975
Disease	level of Phosphatidylethanolamine (18:0_18:2) in blood serum	PDXDC1 RAPSN MAP4K5	1.20e-03	28	222	3	OBA_2045139
Disease	cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	PDXDC1 PMPCA RAPSN CPT1A DNAH1 MAP4K5 PCIF1 MACF1	1.22e-03	276	222	8	EFO_0004612, EFO_0020943
Disease	triglycerides to total lipids in very large HDL percentage	PDXDC1 RAPSN MAP4K5 PCIF1	1.24e-03	62	222	4	EFO_0022339
Disease	free cholesterol in chylomicrons and extremely large VLDL measurement	PDXDC1 EHMT2 RAPSN MAP4K5	1.24e-03	62	222	4	EFO_0022263
Disease	triglycerides to total lipids in IDL percentage	PDXDC1 RAPSN MAP4K5 PCIF1	1.31e-03	63	222	4	EFO_0022329
Disease	free cholesterol to total lipids in medium LDL percentage	PDXDC1 RAPSN MAP4K5 PCIF1	1.31e-03	63	222	4	EFO_0022283
Disease	cortical surface area measurement	USP34 SPRY2 RIN3 ATP8A2 FAM178B RREB1 PMPCA PKD1 PKHD1 FGFR3 TICRR RAPSN RASGEF1A CLSTN1 NR2F1 NR2F2 SEMA3D VCAN MACF1 RORA IL17RD	1.32e-03	1345	222	21	EFO_0010736
Disease	Seizures	ATP7A RNF13 HACE1 NOS1 POLG APEX1 MACF1	1.37e-03	218	222	7	C0036572
Disease	PR interval	DOCK4 OBSCN RYR2 KCND3 MYBPHL SIPA1L2 SPSB3 RAPSN MACF1 KCNMB3 PHLDB2	1.41e-03	495	222	11	EFO_0004462
Disease	chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipid measurement	PDXDC1 RAPSN CPT1A MAP4K5 PCIF1	1.43e-03	109	222	5	EFO_0004639, EFO_0008317, EFO_0008596
Disease	level of Sphingomyelin (d38:1) in blood serum	CERS4 USP24 ANKRD17	1.47e-03	30	222	3	OBA_2045180
Disease	triglycerides in small LDL measurement	RAPSN NRBF2 MAP4K5 PCIF1	1.47e-03	65	222	4	EFO_0022323
Disease	Ciliopathies	MYO7A EVC PKHD1 WDR35 DNAH8	1.49e-03	110	222	5	C4277690
Disease	non-alcoholic fatty liver disease, type 2 diabetes mellitus	ATP8A2 DCLK2 DNAH8 SHC4 PHLDB2	1.49e-03	110	222	5	EFO_0003095, MONDO_0005148
Disease	chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement	PDXDC1 RAPSN CPT1A MAP4K5 PCIF1	1.49e-03	110	222	5	EFO_0004574, EFO_0008317, EFO_0008596
Disease	neuroimaging measurement, brain volume measurement	PDXDC1 USP34 RIN3 SNX31 RAPSN RAB36 VCAN RORA	1.53e-03	286	222	8	EFO_0004346, EFO_0006930
Disease	beta-secretase 1 measurement	SNX31 RORA	1.53e-03	8	222	2	EFO_0009179
Disease	fatty acid desaturase enzyme activity measurement	PDXDC1 RAPSN	1.53e-03	8	222	2	EFO_0009791
Disease	1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) measurement	RAPSN MAP4K5	1.53e-03	8	222	2	EFO_0800455
Disease	progeria (implicated_via_orthology)	VCPIP1 POLG	1.53e-03	8	222	2	DOID:3911 (implicated_via_orthology)
Disease	triglyceride measurement, very low density lipoprotein cholesterol measurement	PDXDC1 RAPSN NRBF2 DNAH1 MAP4K5 PCIF1 MACF1	1.60e-03	224	222	7	EFO_0004530, EFO_0008317
Disease	migraine disorder	DOCK4 NMRAL1 ANKRD36C ZEB2 EHMT2 DMD NSD1 MACF1 WDR12	1.62e-03	357	222	9	MONDO_0005277
Disease	triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement	PDXDC1 PMPCA USP24 CPT1A MAP4K5 PCIF1 MACF1	1.64e-03	225	222	7	EFO_0008317, EFO_0020947
Disease	phospholipids:total lipids ratio	PDXDC1 RAPSN USP24 MAP4K5 PCIF1 MACF1 FRMD5	1.73e-03	227	222	7	EFO_0020946
Disease	fatty acid measurement, linoleic acid measurement	PDXDC1 RAPSN MAP4K5 PCIF1	1.74e-03	68	222	4	EFO_0005110, EFO_0006807
Disease	triglycerides to phosphoglycerides ratio	PDXDC1 RAPSN MAP4K5 PCIF1	1.74e-03	68	222	4	EFO_0022327
Disease	serum albumin measurement	PDXDC1 DOCK4 RIN3 WDR81 SNX8 RAPSN NRBF2 MAP4K5 MACF1 RORA FRMD5 TEDC1	1.87e-03	592	222	12	EFO_0004535
Disease	Todd Paralysis	ATP7A SIRT1	1.96e-03	9	222	2	C0234544

Protein segments in the cluster

Peptide	Gene	Start	Entry
EKGLSLLGYQLCSHR	UMODL1	26	Q5DID0
ALVYRGHSDLVRCLS	BOP1	406	Q14137
ALGYHCDRSLLSSLV	EPG5	1196	Q9HCE0
GKLSEHLRYCDSILR	BRD3	306	Q15059
ALHLVPCSADKDYRS	PRMT2	246	P55345
HALLEKYEELLSKCR	CDR2L	361	Q86X02
LLLHDSSDYLLEACK	CERS4	236	Q9HA82
ISRLQHLLSCYDSGE	B3GLCT	356	Q6Y288
LECSGTISAHYNLRL	LINC00269	81	Q8N2A0
EINSLIRYHCKDGFI	VCAN	3316	P13611
LSIYGLDREDLHCDI	ABCG1	611	P45844
AEKLREYGLSHICSH	ADGB	441	Q8N7X0
AHTHRYLCLDKSVIE	COG4	156	Q9H9E3
LEYSGLKKRHLHCIS	A2ML1	66	A8K2U0
TSLDCLQKLIAYGHI	ARFGEF2	86	Q9Y6D5
SGIDRHLFCLYVVSK	CPT1A	651	P50416
SCRLDTVKYLLDIGA	ANKEF1	601	Q9NU02
ESYHDCVLLFLSRGA	EHMT2	861	Q96KQ7
KALLDASSRHCTYLE	ANKRD36B	1261	Q8N2N9
HIKSSGCFLYLERVL	ANKRD50	296	Q9ULJ7
RDTYSEKSLHRLCGA	CLSTN1	316	O94985
TGIISLCKAHLEDKY	DMD	3201	P11532
RSKALGSDHCPITLY	APEX1	301	P27695
KESALTLACYKGHLE	ANKRD17	401	O75179
AIDLCRYHGNKALEA	PDSS2	361	Q86YH6
SLQEKEHASRLLGYC	DIPK1B	211	Q5VUD6
DLLTLVHSFGYDCRK	CFAP44	131	Q96MT7
ETLCHLEYFATEGLR	ATP8A2	611	Q9NTI2
LYCKGADTILLDRLH	ATP8B2	576	P98198
KIESSLTKHRGILYC	ATP7A	581	Q04656
LTKHRGILYCSVALA	ATP7A	586	Q04656
ELLYHLTRCGKTDDL	NWD2	836	Q9ULI1
LFISKLDGRLSCTEH	NSD1	2191	Q96L73
LKLHCLSESIYRSKG	RAPSN	326	Q13702
DLYVGKTSLIHRFCK	RAB36	131	O95755
AYRALIHSACVKAGE	CRYZ	136	Q08257
DLDTCKGLLPRYEHA	RABEPK	76	Q7Z6M1
ALGNCILDKDYLRSL	RAD52	161	P43351
LKDCLHGIEAKSYSV	CPSF7	396	Q8N684
ALHVDSAEYSCLKAI	NR2F1	311	P10589
HVDSAEYSCLKAIVL	NR2F2	306	P24468
LSLHCTIDEKRLAGY	INTS8	291	Q75QN2
KSDSDLEFYCHLLRG	NPAS2	161	Q99743
HRDLSEKQALCYALS	ARHGEF17	1416	Q96PE2
DVLYLLHSTEKDICL	ANKAR	1131	Q7Z5J8
LHSTEKDICLRAGYA	ANKAR	1136	Q7Z5J8
KALLDASSRHCIYLE	ANKRD36C	1686	Q5JPF3
EGRLILADALCYAHT	LAP3	366	P28838
HLIYACRQLKSSDLD	DNAJC14	271	Q6Y2X3
YSLHNKDVKGALCRL	OR1B1	296	Q8NGR6
HCLEKTTGLSYLVDD	KCND3	481	Q9UK17
LRYLDVSCNKITHDG	LRRC34	296	Q8IZ02
DAGSHYLCLLKARTR	MYLK	466	Q15746
NALLYLRSHVLCKGE	MDN1	3501	Q9NU22
KADLGCRSYTDELHA	IL17RD	721	Q8NFM7
TCRHTAEEYAALLTK	NMRAL1	216	Q9HBL8
RKLFLEAVSSLCGEH	NTSR2	366	O95665
ASLSDLHKFCLGRAL	NUDT19	271	A8MXV4
LYEKSICSGGRLRAH	GLB1L3	456	Q8NCI6
YIRTEGNHGLEKLSC	HECW1	1151	Q76N89
GLLSNVLCRLCSKYH	LIF	146	P15018
SLKDRIHCVAYVLDI	IFI44L	311	Q53G44
SADVRALTYCDLHKI	KCNH6	671	Q9H252
ALTYCDLHKIQRADL	KCNH6	676	Q9H252
AVGAVIYHKLRSDCE	LANCL2	156	Q9NS86
FVLDHSECRVLKSSY	DCLK2	281	Q8N568
RLLSDDYDRIKCHVD	DDX60L	491	Q5H9U9
LHSGIRKLEDYLTSC	DDX60L	601	Q5H9U9
LKRLENCTVIEGYLH	IGF1R	46	P08069
LKCSSLRLIENGYFH	F13B	211	P05160
ITGVSCRDVYAKLLH	FBXO31	126	Q5XUX0
SYLLVGVCSDDLTHK	PCYT1B	106	Q9Y5K3
LGRLLSHKSTISYDA	OR3A2	91	P47893
LGRLLSHKSTISYDA	OR3A3	91	P47888
LAKICRLAIHSRYED	PDXDC1	146	Q6P996
LAKICRLAIHSQYED	PDXDC2P	146	Q6P474
CYKHGPLADDRSRSL	NEMP2	256	A6NFY4
SIYLCRHGESELNLK	PFKFB4	251	Q16877
GYNDSLDTCHKLLLI	DNAH8	3851	Q96JB1
LKDRLLVALHCGSYG	HACE1	891	Q8IYU2
AIESLYRKHCLEQGK	POLG	651	P54098
SECLLYHIKDGVTRV	KIF1C	511	O43896
DSYHKVASDVALLCG	LCT	431	P09848
HDSLKVEKDLRCYGV	NRIP1	166	P48552
VEKDLRCYGVASSHL	NRIP1	171	P48552
RCTDAEKGKGLILHY	GUCY1B1	121	Q02153
NLCLALRGHKTVTYL	NLRP2	746	Q9NX02
SEICDLSAYHALTKL	LRGUK	206	Q96M69
AYGHRQCLELLLERT	ANKRD44	541	Q8N8A2
VRGSELKDCYIHLKV	PRDM10	241	Q9NQV6
GGCQKSLYLETLHAL	MROH1	886	Q8NDA8
NCEARGLESHIKSYL	C17orf75	181	Q9HAS0
YHELLDRAAKCENSL	OSBP	456	P22059
LADLSRKNTDLYHCL	POF1B	261	Q8WVV4
YIRACLDHLAPDSKS	IQGAP3	1511	Q86VI3
LLAAGKYEEAISCHK	NRBF2	21	Q96F24
ELKCLADAQSSYHIL	LRRC8B	6	Q6P9F7
LECTNLYRKGHFTSL	MACF1	521	Q9UPN3
LHLKSTLETGCTEYI	NOS1	321	P29475
LRHVASKDAGVYTCL	OBSCN	6416	Q5VST9
ERKADLIIHLNYCAG	PLA2G4E	716	Q3MJ16
DIHSVSSLCKLYFRE	ARHGAP33	381	O14559
HESAEGKEYLACILR	CPLANE2	16	Q9BU20
LYHGRLLCKTSDAAL	FRMD5	121	Q7Z6J6
DRCYLTLTGALHLKF	DNAH1	1561	Q9P2D7
ISDYLLSNLKGIAHC	HTT	2806	P42858
SVEGICSKIYHISLE	PCIF1	356	Q9H4Z3
SAALRGISCYLKELE	DOC2A	226	Q14183
HCSLFVDLGSSELRK	DOCK4	256	Q8N1I0
CLRSHLGRYLAADKD	FSCN1	61	Q16658
EDLKCIKQLGLTHYR	GBA3	61	Q9H227
CEEILVKHVGSRLYS	FLNA	2601	P21333
TCERGYHDLSVKLLA	FRMPD1	1541	Q5SYB0
YRLGSCLEELKEHID	AKNA	646	Q7Z591
LKSLGYHVCDTLLDF	AGBL2	651	Q5U5Z8
VSDRAEYLGSCLLHK	ACSL5	111	Q9ULC5
KELGLRLLYAVNTHC	ETHE1	66	O95571
KYRALTHLGICSLEI	MYBPHL	306	A2RUH7
LELSHLCEYDFVKLS	MASP2	66	O00187
ARTCHESYDRTALKL	MAN1A2	491	O60476
HLSLLCEKYSTVVRD	KCNMB3	236	Q9NPA1
IFGLDDTYLRCIELH	KHDC1L	36	Q5JSQ8
ASRQHCESEKLLLYD	BRMS1L	141	Q5PSV4
RELALHVEAECSKYS	DDX53	306	Q86TM3
RFYLGHDDDILCLTI	EML5	721	Q05BV3
SVDVDLCIYSLHLKD	EVC	206	P57679
EYLASQKCIHRDLAA	FGFR3	606	P22607
DGYRDTSLLCKAAIH	DCBLD1	191	Q8N8Z6
RLHFDGKYIVCSSAL	FBXW2	331	Q9UKT8
GIVKITSLDGHAYLC	C5orf34	121	Q96MH7
ACLTDTRYKLEGHTV	DNAH2	206	Q9P225
CADVSHKLLRIETAY	PIWIL3	281	Q7Z3Z3
KYLDDVRLSCTLGFH	SCARA3	376	Q6AZY7
EAKLYGRCELARVLH	SPACA3	86	Q8IXA5
YDLLISIHLESACRS	RYR1	1711	P21817
DSLLHTVYRLSKGCS	RYR2	2546	Q92736
FTLSLLGHVYCKTDR	CDC27	116	P30260
DSGHVRLRLCKNLSY	CDH16	506	O75309
DIKRCLGYHLDVSLA	C9	376	P02748
AGIDRHLFCLYLVSK	CPT1B	651	Q92523
ATYRHLLEGEDCKLP	KRT36	391	O76013
TLGLQRCDTHLVAYK	LRRN4	711	Q8WUT4
CRETLQGLAYLHTKG	MAP4K5	121	Q9Y4K4
LLVTLLASYGDASCH	PKD1	3681	P98161
DDALPHCIKGYLLRS	RIN3	936	Q8TB24
EHLVDCARKYLLGVQ	PMPCA	261	Q10713
DLALSAHIKILDYSC	USP9X	526	Q93008
HGLGSHKYTLDVELC	UVSSA	296	Q2YD98
HKYTLDVELCSEGLK	UVSSA	301	Q2YD98
LDLLQSYKDLCERHE	SNX8	321	Q9Y5X2
KLKEHEDYCGARTEL	TRAFD1	101	O14545
LCRKYHSAELESLGR	SYNE1	2366	Q8NF91
ILAYIDGLETEKCLH	SCYL1	76	Q96KG9
VHLLLSYLCAKGATE	AATK	391	Q6ZMQ8
TLVTYLDVRSCLGHL	RHOT2	366	Q8IXI1
KSLQSLYREHCEAIL	RFX3	351	P48380
EGLDSAKRCTQALYH	YARS2	361	Q9Y2Z4
CTLYEERLHEATAKL	MYH15	1261	Q9Y2K3
DISLGHIYKFLALCA	FAM178B	421	Q8IXR5
HTLDTCLKLDDTVYL	FASTKD2	541	Q9NYY8
EEYCSNHEKALRLLV	PREX1	146	Q8TCU6
EYEDGDKLRILPCSH	RNF13	246	O43567
SDEELGLLCHHTSYL	SIPA1L2	1591	Q9P2F8
INELCHRLGGEYAKL	SIRT1	486	Q96EB6
EPYRLHESCKDLTTA	SLC12A1	996	Q13621
EYCLGSASDLLEVHK	TAOK1	106	Q7L7X3
EYCLGSASDLLEVHK	TAOK2	106	Q9UL54
GHIFCTLESLKRYLG	TELO2	26	Q9Y4R8
RLSCGDTHLLKLVAF	OR6T1	186	Q8NGN1
HLYKESGLDNCTRIS	PKHD1	3131	P08F94
DKYRHTFCSLLGRDE	SPSB3	176	Q6PJ21
DIRCQKGYELHGSSL	SRPX	86	P78539
YRCHRKDSLPDADLA	PHLDB2	506	Q86SQ0
SVLLLSCKDHVGYIF	SLC47A1	351	Q96FL8
VSHKIGLCRELLGYF	SNX31	146	Q8N9S9
LSKEDLGLHAYRCED	SPRY2	166	O43597
YHGRLTKQDCETLLL	SH2D1B	6	O14796
LVQLSLHRCDTYGKA	SEMA3D	526	O95025
SEDLYHRCLQSVLEG	CHPF	741	Q8IZ52
CYHGKLSRKAAESLL	SHC4	526	Q6S5L8
LCGVKYSARLSIRDH	ZFHX4	2966	Q86UP3
GELIHCLAELYQRKS	TICRR	531	Q7Z2Z1
LHAEAISLLKSGRFC	VPS11	646	Q9H270
RLLSYCKGRDHGVLD	ZSWIM9	166	Q86XI8
RTHEIIHTGEKLYDC	ZNF136	156	P52737
LEYCKHLNSHLSEGI	ZNF639	416	Q9UID6
CEYSTGQIEDLKIHL	ZNF639	436	Q9UID6
ICGKLLSAAYITSHL	VEZF1	291	Q14119
EHNLDLLRYEKGCVR	ZNF568	186	Q3ZCX4
KFGESIEDLHTCRLL	PIGX	66	Q8TBF5
HRCRGDLTKTYSLEA	RASGEF1A	251	Q8N9B8
HIYCTGRLEKHLELF	STAG3	611	Q9UJ98
RCTHYLKPLLEAGTS	UBA7	551	P41226
CDYIAADKAALIRHL	RREB1	676	Q92766
SKSHLETCQYLREEL	RORA	281	P35398
ALLLHCYADSGCKLL	SCGB2A1	11	O75556
LGCLRLTEADYLSSH	NUDT16L1	86	Q9BRJ7
KLDIDKSVRHLYICD	SAP30L	61	Q9HAJ7
RYLAKEGCALAHLTL	TONSL	1241	Q96HA7
ALLSKIHLYTRGCHS	TEDC1	191	Q86SX3
AYRTLAILGCLNKHV	HEATR9	201	A2RTY3
DLGHILDFTCRLKYL	NISCH	176	Q9Y2I1
RRYGSCGLEDLHLRK	ZNF682	101	O95780
YVSKISSDCDDILHL	ZDBF2	446	Q9HCK1
AVAYLTGKRLCLDLD	NDST2	296	P52849
DLIKHYNCGDLSSVI	TRABD2A	251	Q86V40
CLFSALLGYDISEKL	POPDC2	231	Q9HBU9
GKDRSGSLLYLHDTL	VCPIP1	181	Q96JH7
NCGEHDTTEYKLRTL	PTPN6	381	P29350
RGQLLEDDKHLSDYC	UBL4B	46	Q8N7F7
ECGKSYRLISLLNLH	ZBTB17	366	Q13105
REESLGKCLLASTYL	USP24	146	Q9UPU5
AHGSYLKVESELERC	TTC7A	6	Q9ULT0
CGKALDCLSLYLTHE	ZNF491	136	Q8N8L2
LHSRFIGASLDVKCL	TMEM117	381	Q9H0C3
CLSLYLIHKRTHTGE	ZNF625	136	Q96I27
DGTRHLDLPCKRSYL	TBX4	341	P57082
ETAVRHESCSGLYKL	USP34	1666	Q70CQ2
DTRSCKAPLYDLAAH	WDR12	371	Q9GZL7
CDRGYKRLTSLKEHI	ZEB2	216	O60315
SDLTHLAALAYKCLA	TIGD5	511	Q53EQ6
HYLSERDACKILIAD	TSNAXIP1	186	Q2TAA8
YEGCVDTALKTALHL	WDR35	1041	Q9P2L0
SSGAVDYCLHVLKSL	UBR4	3091	Q5T4S7
KCHFYEVLSEIKRLG	VIRMA	556	Q69YN4
CREYFHKLLIQGDSS	WDR7	336	Q9Y4E6
TLLAGSLAKALCYIH	GTF2H3	131	Q13889
CGALSLYHIAVDEKL	WDR81	281	Q562E7
LYHIAVDEKLCSELR	WDR81	286	Q562E7
YIHTEASESLCGLKL	TIMP3	81	P35625
LNELGRHKEAYECSS	ZC3H7B	126	Q9UGR2
YHGACLDTALTARKR	KMT2D	251	O14686
YHKCTREEVLQLGAL	MYO7A	2026	Q13402
CSREDAIHLAGLIYK	MYO7B	1926	Q6PIF6
LYRKHRLESGACFDI	MYRIP	141	Q8NFW9